Laser therapy for genital lichen sclerosus: A systematic review of the current evidence base by Tasker, F. et al.
Received: 11 April 2021 - Revised: 19 May 2021 - Accepted: 22 May 2021DOI: 10.1002/ski2.52
SYS TEMAT I C REV I EW
Laser therapy for genital lichen sclerosus: A systematic
review of the current evidence base
F. Tasker1 | L. Kirby2 | D. J. C. Grindlay2 | F. Lewis1 | R. C. Simpson2
1King’s College London, St John’s Institute of
Dermatology, London, UK
2Centre of Evidence Based Dermatology,
University of Nottingham, Nottingham, UK
Correspondence
Fiona Tasker, King’s College London, St
John’s Institute of Dermatology, London, UK.
Email: fiona.tasker@kcl.ac.uk
Abstract
Background: Lichen sclerosus (LS) is a chronic, inflammatory dermatosis.
Initial treatment with superpotent topical corticosteroids is the accepted and
evidence‐based first‐line therapy. For those who do not respond after
exclusion of other potentiating factors, the best second‐line therapy is un-
clear. Laser therapy is an emerging treatment for genital LS and despite
uncertain efficacy its use is gaining popularity in the private sector.
Objectives: We aimed to review the effectiveness of laser therapy for
genital LS in men, women and children.
Methods: We conducted a systematic review of all primary studies
reporting the use of laser in genital LS. Ovid MEDLINE, PubMed, Ovid
Embase, Cochrane CENTRAL, Web of Science, CINAHL and PsycINFO
were searched from inception to February 2021. The quality of the studies
was assessed using the revised Cochrane risk‐of‐bias tool for randomized
trials, ROBINS‐I tool for non‐randomized trials and Joanna Briggs Institute
checklist for case studies.
Results: A total of 24 studies, involving 616 adults, met inclusion criteria.
These were six randomized controlled trials (RCTs), one non‐randomized
trial, nine single arm trials and eight case series. Where assessed, most
studies suggest that laser therapy in patients with LS may improve symp-
toms, clinical signs, quality of life and sexual function. However, results
were highly heterogeneous and methodological quality was very low,
therefore meta‐analysis was not possible.
Conclusions: There is poor evidence to support the use of laser therapy for
genital LS at present. Effectiveness of laser needs to be robustly investi-
gated in well‐conducted RCTs.
1 | INTRODUCTION
Lichen sclerosus (LS) is a chronic, inflammatory
dermatosis, with predilection for genital skin. The inci-
dence of LS is 1.6% in women by age 80.1 Symptoms
include intense itch, soreness and dyspareunia.
Anatomical changes with resorption of the labia minora
and fusion of the clitoral hood can occur. Scarring from
dermal inflammation causes anatomical alteration. In
males, LS typically occurs on the glans penis and
foreskin, leading to phimosis, difficulty with micturition
and dyspareunia.2 LS also affects children although this
is less common. LS has considerable impact on quality
of life and psychosocial and sexual well‐being.3,4 In
addition, a small proportion (3%–5%) develop malig-
nancy.5–7
First‐line treatment with super‐potent topical corti-
costeroids is the accepted evidence‐based therapy.8
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It is unusual for female patients not to respond to topical
steroids, and if there is ongoing active disease, it is
important to investigate for another cause. Lack of
compliance, secondary infection, contact dermatitis to
treatment, development of vulval neuropathic pain and
most importantly, progression to differentiated vulval
intra‐epithelial neoplasia all need to be excluded. In
males who have severe phimosis or meatal involve-
ment, surgical treatment would be required as topical
steroids would not help this. The most effective second‐
line therapy is unclear.
‘What surgical treatments should be offered for
lichen sclerosus?’9 was a research question prioritized
during the Lichen Sclerosus Priority Setting Partnership
in 2018. Surgical treatments were defined to include
(but not limited to) laser, platelet‐rich plasma and
lipofilling.
Laser is an emerging treatment for genital LS.
Despite uncertain efficacy, its use is gaining popularity.
Statements have been issued by international bodies to
warn that lasers used for vaginal rejuvenation can cause
serious harm10 and laser should not be used to treat LS
outside the context of well‐conducted clinical trials.11
The aim of this systematic review (PROSPERO
database registration‐CRD42019143039)12 was to
establish the effectiveness of laser therapy for genital
LS affecting men, women and children. All types of
laser (any regimen, any time frame) were considered;
the comparator was either active or placebo and the
main outcomes assessed were (i) clinical signs, (ii)
patient‐reported symptoms, (iii) quality of life and (iv)
sexual function.
1.1 | Patients and methods
Ovid MEDLINE, PubMed, Ovid Embase, Cochrane
CENTRAL, Web of Science, CINAHL and PsycINFO
were searched from inception to February 2021.
PubMed search strategy used the following terms: (‘LS’
or ‘lichen sclerosis’ or ‘lichen sclerosus et atrophicus’
[MeSH Terms] or ‘vulvar lichen sclerosus’ [MeSH
Terms] or ‘balanitis xerotica obliterans’ [MeSH Terms]
or ‘balanitis xerotica’ or BXO) AND (laser or lasers or
‘lasers’ [MeSH Terms] or ‘laser therapy’ [MeSH Terms])
Randomized controlled trials (RCTs), non‐
randomized designs, cohort studies or case series
with five or more participants were included. Studies
including photodynamic therapy using laser as the
source of light and articles in languages other than
English were excluded.
An information specialist conducted the searches,
screening took place independently by three authors,
and data extraction/quality assessment were per-
formed independently by two reviewers with a third
reviewer to resolve any disagreements. Quality
assessment was performed using published tools
where available for the identified study types: the
revised Cochrane risk‐of‐bias tool13 (RCTs), ROBINS‐I
tool14 (non‐randomized trials) and The Joanna Briggs
Institute checklist15 (case studies). Data were extrac-
ted into an Excel spreadsheet (Table 1 summarizes
the data and full details of what was extracted can be
found on PROSPERO).12 Reference lists of the
included studies were also reviewed as well as the
clinicaltrials.gov website.
2 | RESULTS
Of 360 studies, 24 studies met the inclusion criteria,
with a total of 610 participants (Figure 1) (women and/or
men, but no children). The results of the studies are
summarized in Table 1.
2.1 | Randomized controlled trials
Of six identified RCTs,16–21 three were conference ab-
stracts16,17,20 and all included female participants.
Laser was compared with either topical corticoste-
roid16,17,18,20 sham laser19 or ultrasound.21
Four studies used different types of laser (diode
laser, non‐ablative neodymium: yttrium aluminium
garnet (Nd:YAG) laser and fractional CO2 laser) with
differing regimens in women with biopsy proven LS
(except one study which did not state how LS was
confirmed),16 were compared against short courses (4–
8 weeks) of superpotent topical corticoste-
roids.16,17,18,20 A variety of outcomes were used in
What's already known about this
topic?
� A super‐potent topical steroid is the
evidence‐based first line therapy for genital
lichen sclerosus (LS).
� For those who do not respond to treatment,
after exclusion of other potentiating factors,
the best second‐line therapy is unclear.
� Laser therapy is an emerging treatment for
genital LS and despite uncertain efficacy, its
use is gaining popularity in the private sector.
What does this study add?
� There is not enough evidence to recommend
laser for the treatment of genital LS.
� There is a lack of long‐term data on the
procedure.
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these RCTs; clinical signs such as skin thickness and
histology, patient reported symptoms, quality of life
scores and sexual function. Results suggest that pa-
tients allocated to receive laser had significant
improvement in skin thickness (increased by 49.07%
vs. −27.51% in the corticosteroid group, p = 0.006).16
There was no significant difference in improvement of
clinical photographs from baseline and 3 months after
treatment (0.58 +/− 1.25 in the laser group and
−0.27 +/− 1.27 in the control group).18 Symptoms
including itch, burning and pain rated on a visual
analogue scale were reduced in both groups compared
with baseline but they were statistically significantly
better in the laser group at one and 3 month follow up
and the effect was still significant at 6 months, although
these symptoms started to increase again.18 Belotto
et al., 2019 states decreased itch in both groups but no
numbers are given17 and Belotto et al., 2016 states itch
decreased less in the laser group compared to the
topical corticosteroid group (by 50% vs. 83.76%).16
Improved Skindex‐29 score, a measure of quality of life,
was demonstrated in both groups. At 6 months, the
laser only group had the best reduction in Skindex
score (baseline was 45.52 (15.2SD) and 23.1 (18.9SD)
at 6 months) and the steroid only group had the least
(baseline score was 51.22 (15.2SD), at 6 months it was
44.40 (17.0SD)). However, the score was similar at 12
months for the laser group (22.32 (23.4SD) versus
37.92 (22.7SD) for the topical steroid group). After
crossing over at 6 months, the steroid to laser group
had a greater decrease in score than the laser to
steroid group and in terms of satisfaction measured by
PGI‐S, the steroid to laser group were significantly
more satisfied than the laser to steroid group, however
there was no statistical comparison between the
groups at any point.20 The impact of LS on the quality
of patients’ sex life was reduced significantly only in
the laser group but the problems recurred at 6‐month
follow‐up.18
Mitchell et al. was the only RCT to compare CO2
laser with sham laser treatment. Forty women with LS
were randomized in a 1:1 ratio to receive either five
fractional CO2 treatments or five sham treatments in a










F I GURE 1 PRISMA 2009 Flow Diagram
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and although there was improvement in Histopathologic
Scale (HS) in the active treatment group, the change in
HS between the active and sham arm was not statisti-
cally significant (−0.17; 95% CI = −1.14, 1.06,
p = 0.78). There was an improvement in the patient‐
reported Clinical Scoring System for Vulvar Lichen
Sclerosus (6.82‐point reduction from baseline in the
active (95% CI = −11.28, −2.37, p = 0.004) and a 4.83‐
point reduction in the sham treatment group (95%
CI = −9.16, −0.51, p = 0.03). However, when the cli-
nicians completed this scoring system, a 0.82 increase
(worsening) was found in the active treatment group
(95% CI = −0.46, 2.11, p = 0.20) and a 0.28 reduction
in the sham treatment group (95% CI = −1.53, 0.97,
p = 0.65), although the results were not significant. The
authors conclude that CO2 laser is not an effective
monotherapy treatment for vulvar LS but suggest it may
be a useful adjunct to topical steroids.19
One RCT included 60 females with ‘white lesions
of the vulva’ (12/60 had biopsy‐proven LS). Partici-
pants were randomized to either fractional ultra‐pulsed
CO2 laser or high‐intensity focused ultrasound (US).
Compared to focused US, clinical signs of colour,
elasticity and symptoms of pruritis were ‘cured’ in 1
participant in the laser group and 0 in the US group;
‘basically disappeared’ in three in the laser group and
two in the US group; ‘improved’ in one in the laser
group and two in the US group; and was ‘ineffective’ in
one in the laser group and two in the US group.
Statistically improved outcomes across all patients
with ‘white lesions of the vulva’ were stated for total
cured (p = 0.01) and total effective rate (p = 0.02).
The results for LS patients were not reported sepa-
rately. Overall risk of bias using the Cochrane risk‐of‐
bias tool was high for all of these RCTs.21
2.2 | Non‐randomized trials
There was one non‐randomized trial comparing frac-
tional CO2 versus topical triamcinolone acetonide for
six weeks to treat vulval LS.22 The authors state the
skin elasticity score in the laser group was statistically
lower than that of the topical steroid group at 6 months
after treatment (p < 0.05). Itch and dyspareunia were
reported as being statistically significantly better after
treatment in both groups but no further details were
given in this abstract. Overall risk of bias using
ROBINS‐I tool was high.
2.3 | Single arm trials
Of nine single arm trials,23–31 seven were studies of
women with vulval LS and two included men with
genital LS.26,31 The intervention was ablative Er:YAG
laser in 1 study, non‐ablative Er:YAG in 1 study,24,27
and fractional CO2 laser 6, with ablative CO2 in one.
One study using fractional (sub‐ablative) CO2 had
additional treatment with autologous plasma and im-
munity modulation with nutrition factors.25 The latter
study states 50% of participants (9/18) were asymp-
tomatic and 4 had reduced itching and dyspareunia
although one continued with severe dyspareunia but
her itching improved.
There were some clinical improvements observed
including: visible improvement in skin colour, elasticity
and vascularity, reduced elasticity, atrophy and fis-
sures,26 significant improvement of ecchymosis, ex-
coriations and hypopigmentation27 and improved
whitening, elasticity and lichenification, although mod-
erate to severe labial fusion improved in only four of
the 11 subjects.28 Symptoms that were reported to
improve include itching,23–25,27,29,30 vulvar discomfort,
pain or soreness,23,24,27 dryness, burning, bleeding,
easy tears and ulcerated lesions.24 Quality of life was
reported to improve in two studies27,28 and some pa-
tients stated improved sexual function25,26,28–30
although skin tearing worsened in 50% (3/6) in one
study.28
2.4 | Case series
Of eight case series,32–39 six included women with
vulval LS and two included both men and women with
genital LS.13,39 All studies used CO2 laser except one
which used blue diode laser.36 Improved clinical signs
include decreased white epithelium by 20%,32
improved erythema, oedema and erosions36 no visible
recurrence of disease (5/7)38 and improvement in the
appearance of the introitus,39 however one study
mentioned urethral lesions of one patient recurred
despite three separate treatments (n = 5 males) and
LS recurred in one female patient with perineum LS
(n = 2).35 Studies report 65% improvement of symp-
toms (range 10%–100%),33 18/21 questions assessing
symptoms significantly improved,34 symptom score
decreased from 5.25 to 2.75,36 there was a statistically
significant reduction in vaginal pain, itch and dysuria,32
resolution of itch in 5/7 patients,38 pruritus dis-
appeared in 50% and reduced in the other 50% as
well as resolution of burning in 60%, however there
was little improvement in urinary problems.39 One
study reports DLQI score decreased from 5.75 to
3.75.36 Other studies report a statistically significant
reduction in dyspareunia32 and 2/9 with dyspareunia
had complete resolution.39
Meta‐analysis was not possible due to high hetero-
geneity of studies and low methodological quality.
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3 | DISCUSSION
We note a recently published systematic review40
which performed meta‐analysis on two of the RCTs
which were also identified in our study (Bizjak 2019
and Burkett 2020).8,41 The latter is a conference ab-
stract, later published by Siddique et al in 2020.20 We
assessed these studies as having high risk of bias.
Outcome measures used to assess symptom score
were very different (total symptom score vs. Skindex
29). The reports lacked the necessary detail required
to independently calculate odds ratios and therefore,
meta‐analysis was not possible. In addition, the sys-
tematic review by Li only looked at 13 studies; they did
not include an additional 13 studies that we identi-
fied,16,17,19,21,22,25,26,28,31,33–36 four of which were
RCTs.16,17,19,21
There are many limitations of the studies identified in
our systematic review. Conference abstracts (not peer
reviewed) comprise 9 of the 24 included studies. Of the
six RCTs, three were published in peer reviewed journals
and only two18,19 had a prospectively published protocol,
despite all having been commenced after the introduc-
tion of mandatory trial registration guidelines.42 All RCTs
identified were assessed to have a high risk of bias. In
studies where the control group received topical steroids,
the topical regimen was often shorter than 12 weeks,
which is the recommended duration of treatment.8 The
one non‐randomized trial (serious risk of bias) did not use
super‐potent topical corticosteroids in the control
group.22 The single arm trials are subject to considerable
bias due to study type. Many studies are also under‐
powered. Published case series lacked methodological
detail and confounding factors, including concomitant
use of topical treatments such as oestrogen during laser
treatment were noted.32,37 7/24 of the studies were either
commercially funded or declared conflicts of interest and
11/24 did not include conflicts of interest/funding
statement.
Three studies included patients without biopsy‐
proven LS and a further three did not state how LS
diagnosis was confirmed, therefore there may be con-
ditions which can mimic LS clinically included in these
studies. The period of follow up after the last laser
treatment was short in the majority of studies; between 1
month and 12 months in 16/24 studies; 11 of these fol-
lowed up patients for 6 months or less. Three studies
followed up the participants between 6 and 48
months29,37,38 and another study between 3 months and
6 years35 Three studies did not report the duration of
follow‐up. Only one retrospective study had a long follow
up period of 14 years; however not all patients were alive
at follow up and those who were, were contacted by email
or telephone and only symptomatic patients were invited
to clinic for clinical examination to confirm the presence
of no lesions.31
The limitations of this systematic review includes a
lack of detailed data from some of the abstracts which
published limited information and possibly the exclusion
of negative studies due to publication bias. There are
seven ongoing registered trials of which the results are
awaited43–49; five of which are RCTs.44,46,47,48,49
In summary, there is no high‐quality evidence to
support the use of laser for the treatment of genital LS
in males and females. Long‐term data of laser are
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